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Abstract
Dyslipidemia has been proven to play an important role in the occurrence and development of the ischemic stroke and
lipid-lowering therapy could significantly decrease the risk of the ischemic stroke. However, the association between lipid
levels, lipid-lowering therapy and the risk of intracerebral hemorrhage (ICH) is not clear. Studies have shown that low
serum levels of total cholesterol might be associated with increasing risk of ICH, whereas the SPARCL study, a large
prospective, randomized, placebo-controlled trial, demonstrated an increased risk of hemorrhagic stroke during high-dose
statin therapy among the patients with previous stroke. The relationship between lipid-lowering therapy and ICH has
become a hot topic in the recent years. We searched PubMed for articles published in English to review the existing
evidence on the association of lipid levels, statin therapy and risk of ICH as well as the underlying mechanisms in order to
provide practical recommendations for clinical decision-making and a foundation for further researches.
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Background
Stroke is one of the leading causes of death and adult
disability in the world. Intracerebral hemorrhage (ICH),
an important subtype of the stroke, is characterized by
high mortality and morbidity, which contains symptom-
atic intracerebral hemorrhage (sICH) [1] and cerebral
microbleed (CMB) [2]. In ICH patients, perihematomal
inflammation where the region becomes infiltrated with
neutrophils and activated microglia after the activation
of Toll-like receptor 4 [3] and the release of inflamma-
tory mediators such as tumor necrosis factor-α (TNF-α)
and interleukin-1β (IL-1β) [4] contributes to neuronal
injury and functional disability. Meanwhile, ICH results
in the change of the cerebral blood flow and the increas-
ing permeability of blood–brain barrier (BBB) [5]. These
pathological changes could aggravate nerve damage and
dysfunction. The data from World Health Organization
(WHO) showed that ICH accounts for approximately
25–50 % of stroke and the reduction of morbidity and
mortality among ICH patients must remain a public
health priority.
Hyperlipidemia has been proven to be a risk factor of
ischemic stroke [6]. Statins which mainly reduce the
serum levels of total cholesterol (TC) and low density
lipoprotein cholesterol (LDL-C) are widely used or pre-
scribed for the primary and secondary prevention of is-
chemic strokes and have achieved favourable clinical
outcomes. Several clinical studies [1, 7–9] have shown
that statin could not increase the risk of ICH and has
been beneficial to ICH patients as well as promoting
their recovery. But a post hoc analysis of the SPARCL
trial that was conducted among the patients with stroke
demonstrated that atorvastatin was associated with an
increased risk of ICH [10]. Furthermore, some epidemio-
logical and case–control studies found that patients with
lower serum lipid had an increasing risk of ICH [11–13].
Therefore, it is necessary to further clarify the associ-
ation of serum lipid levels, statin therapy and the risk of
ICH. The systematic review focuses on the research pro-
gress in this field derived from epidemiological and clin-
ical evidence. We searched PubMed for basic and
clinical studies which were published in English (last
search update performed on 31 August 2015). The
search strategy was based on the combination of the fol-
lowing terms: lipids, total cholesterol (TC), triglyceride
(TG), low density lipoprotein cholesterol (LDL-C), and
high density lipoprotein cholesterol (HDL-C), lipid-
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lowering therapy, statins, HMG-CoA reductase inhibi-
tors, stroke and intracerebral hemorrhage.
Blood lipid levels and ICH
Lipids are essential components of cell membrane,
which play an important role in maintaining the
stabilization of endothelial cells and the integrity of cere-
bral small vessels [14]. Epidemiological and case–control
studies found a correlation between ICH and the change
of blood lipid levels which included TC, TG, LDL-C,
and HDL-C.
TG and ICH
A pooled cohort study of the Atherosclerosis Risk in
Communities Study (ARIC) and the Cardiovascular
Health Study (CHS) involving 21,680 patients showed
that lower TG was a risk factor for ICH and was in-
versely related to the incidence of ICH [15]. In a
population-based prospective cohort study among 8393
men and women [11], Bonaventure et al. made a quanti-
tative analysis of TG level and the risk of ICH, demon-
strating that a low level of triglycerides (serum TG
≤0.94 mmol/L) was associated with a more than two-
fold increased risk of ICH [adjusted hazard ratio (HR)
2.35, 95 % confidence interval (CI) 1.18–4.70]. In
addition, the Rotterdam Study showed that serum TG
levels were associated with the presence of CMB [16],
which is a risk marker of sICH [2]. The above results
suggest that the low TG might be related to the increas-
ing risk of ICH. On the contrary, in the Malmö Prevent-
ive Project [17] involved 33,346 participants (mean age
47 years old), 147 ICH subjects who were followed up
(approx. 14 years) had significantly higher TG levels (1.7
vs. 1.4 mmol/L) compared with 1029 stroke-free con-
trols, matched for age, sex and screening-year. The
multivariate analyses showed there was a positive correl-
ation between TG and the risk of ICH among the lobar
ICH (OR 1.7, 95 % CI 0.9–3.2) and nonlobar ICH (OR
1.4, 95 % CI 0.90–2.3) patients. Furthermore, a cross-
sectional study [18] demonstrated that 500 patients with
acute ICH had significantly higher TG levels (P <
0.0001). The linear regression and correlation analysis
suggested that with increased TG, the intracerebral
hemorrhagic volumes were gradually increasing.
TC and ICH
In a case–control study in 22 countries (the INTER-
STROKE study) [13], with blood analyses completed
among 2190 cases and 2127 controls who matched for age
and sex, researchers found that increased concentration of
TC was associated with reduced risk of ICH (OR 0.62,
99 % CI 0.42–0.92). A meta-analysis [19] that included 23
prospective studies, totaling 1,430,141 participants with
7960 hemorrhagic strokes (0.56 %) demonstrated that the
summary relative risk of hemorrhagic stroke was 0.69
(95 % CI 0.59–0.81) in high versus low TC analysis. Mean-
while, the summary relative risk of hemorrhagic stroke for
1 mmol/L increment of TC was 0.85 (95 % CI 0.80–0.91),
supporting that TC was inversely related to ICH. And Su-
zuki et al. [20] found that serum TC <160 mg/dl corre-
lated with the significantly increased risk of ICH.
Furthermore, the Framingham Heart Study [2] comprised
1965 Framingham residents (mean age 66.5 ± 11.0 years
old; 54 % women) who attended a baseline brain MRI be-
tween 1998 and 2008 and underwent it again between
2000 and 2009. The result revealed that 8.8 % of partici-
pants had a CMB between 2000 and 2009. Logistic regres-
sion analysis [2] showed that TC < 10th percentile
remained associated with the increasing risk of CMB (OR
1.9; 95 % CI 1.20–3.03). However, a prospective study [12]
including 58,235 Finnish participants (age range 25–74
years old) without a history of coronary heart disease and
stroke demonstrated that, after further adjustment for
other confounding factors, the inverse association between
TC and ICH is only significant in women but not in men.
LDL-C and ICH
The meta-analysis conducted by Wang et al. [19]
showed that the summary relative risk of hemorrhagic
stroke for 1 mmol/L increment of LDL-C was 0.90
(95 % CI 0.77–1.05), suggesting that high level of LDL-C
may reduce the risk of hemorrhagic stroke. Moreover,
Mustanoja et al. [21] found that after adjusting for
known ICH prognostic factors lower LDL-C levels was
independently associated with in-hospital mortality of
ICH patients (OR 0.54, 95 % CI 0.31–0.93).
HDL-C and ICH
A case–control study [13] showed that the level of HDL-
C positively correlated with the risk of ICH (OR 1.91,
99 % CI 1.29–2.83). In addition, higher ratio of non-
HDL-C to HDL-C was associated with reduced risk of
ICH (OR 0.43, 99 % CI 0.30–0.62) [13]. A meta-analysis
[19] of 19 prospective cohort studies also indicated that
the summary relative risk of hemorrhagic stroke for
1 mmol/L increment of HDL-C was 1.17 (95 % CI 1.02–
1.35) in a dose–response analysis, which suggested that
the increased level of HDL-C may be related to a higher
risk of ICH.
Table 1 outlines the details of major studies investigat-
ing the relationship between lipid levels and ICH. Most
research show that lower TC and LDL-C and higher
HDL-C are associated with the increasing risk of ICH.
Although the precise mechanisms are still unclear, it was
considered that low blood level of TC might contribute
to an abnormal fragility of erythrocytes [22] and endo-
thelial cells [23], necrosis of smooth muscle cell in arter-
ial media [19], and angionecrosis [23]. But the
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Table 1 Summary of studies investigating the relationship between lipid levels and ICH
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relationship between TG and ICH is controversial. The
inconsistent results might be due to the different partici-
pants involved in the researches or other factors. The
subjects who participated in the Malmö Preventive Pro-
ject [17] were younger and the follow-up period was
shorter than those who participated in the projects
which had opposite results. In Zhou’s cross-sectional
study [18] TG level was tested after the acute ICH oc-
curred, which was different from the prospective studies
in which TG level was tested before the ICH occurred.
Therefore, a higher TG level may be the result of stress
[24] instead of a risk factor for ICH. These data suggest
that the association between TG and ICH may be incon-
sistent in different individuals.
Statin therapy and ICH
Statins, also known as 3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA) reductase inhibitors, have been
widely used clinically. A large number of studies has
shown that statin therapy is an effective method for the
treatment and prevention of atherosclerotic cardiovascu-
lar diseases. However, there is a concern whether lower-
ing lipid levels by statin therapy may increase the risk of
ICH. Table 2 outlines the details of major studies investi-
gating the relationship between statin use and ICH. As
shown in the Table 2, these results are not consistent.
Statins may improve the outcome of ICH
After analyzing the clinical data of 2466 patients with
ICH, Dowlatshahi et al. [25] found that the patients who
took statin before the occurrence of ICH had lower risk
of severe ICH compared with the nonusers (54.7 % vs.
63.3 %). In addition, among 537 statins users, 158 pa-
tients who discontinued its use on admission were more
likely to have poor outcomes and higher 30-day mortal-
ity (71 % vs. 21 %, P < 0.01) compared with those who
took statin continuously [25]. A retrospective cohort
study showed that ICH patients who started statin ther-
apy during hospitalization had a lower 30-day mortality
rate than statin nonusers (18.4 % vs. 38.7 %, P < 0.001)
and were more likely to be discharged to their homes or
an acute rehabilitation facility (51.1 % vs. 22.3 %, P <
0.001) [9]. Pan et al. [26], using a multivariable logistic
regression model adjusted for confounding factors, dem-
onstrated that statin use during hospitalization for ICH
patients was associated with more than 50 % lower mor-
tality rate at 3 months (adjusted OR 0.44, 95 % CI 0.22–
0.87, P < 0.001) and 1 year (adjusted OR 0.49, 95 % CI
0.27–0.86, P = 0.02) compared with those without statin
therapy during admission.
It is believed statin may have the pleiotropic effects be-
sides reducing serum lipid level. Using Magnetic Reson-
ance Image (MRI) and immunohistochemistry, Yang
et al. [27] found that simvastatin may protect the
integrity of the blood–brain barrier (BBB) to prevent the
dysfunction of it, resulting in the reduction of neuro-
toxic substances and white blood cells into the brain
parenchyma [28, 29]. In addition, quantitative analysis
showed simvastatin could improve the cerebral blood
flow (CBF) and promote the functional recovery of cere-
brum [27]. In experiments with rats, it was demon-
strated that statins could reduce the activation of glial
cells [30] and the release of the cytokines such as IL-1B
and TNF-α by microglia and brain-derived neurotrophic
factors [4], suppress phagocytosis of microglia [4], in-
hibit the oxidative stress and development of inflamma-
tory reaction [30], decrease the cell necrosis around the
hematoma [30, 31], and promote the recovery of the
sensorimotor function [31]. Yang et al. [32] found that
statins could also promote the hyperplasia of the epen-
dymal lower cells in Wistar rats and the formation of
synapses and increase vascular density in the hematoma
boundary zone, resulting in a better functional recovery
of the nervous system.
Statins may be independent of ICH
A randomized and double-blinded trial [33], in which
20,536 adults with cerebrovascular disease, coronary
heart disease, other occlusive arterial disease, diabetes or
hypertension were randomly allocated 40 mg simvastatin
daily or matching placebo, indicated that statin therapy
was not associated with hemorrhagic stroke (0.5 % vs.
0.5 %, OR 0.95, 95 % CI 0.65–1.40, P = 0.8) during a
mean 4.8 year follow-up period. A retrospective cohort
study [34] involving 17,872 subjects aged 66 years and
older who initiated statin therapy after acute ischemic
stroke, demonstrated that there was no association be-
tween statin and ICH by the analysis comparing statin
users with non-users (OR 0.87, 95 % CI 0.65–1.17).
Hackam et al. [35] conducted a meta-analysis of 23 ran-
dom trials and 19 observational studies (12 cohort stud-
ies, six case–control studies and one case-crossover
study) which comprised 248,391 patients with athero-
sclerotic cardiovascular disease or risk factors for athero-
sclerosis, of which 14,784 were ICH patients. And the
results showed there was no significant association be-
tween statin use and ICH in the random trials (OR 1.10,
95 % CI 0.86–1.14), cohort studies (OR 0.94, 95 % CI
0.81–1.10) and case–control studies (OR 0.60, 95 % CI
0.41–0.88). McKinney et al. [36] made a meta-analysis of
31 randomized controlled trials about statin therapy and
a total of 182,803 subjects were included (91,588 in the
active group and 91,215 in the control group). Three
hundred and fifty-eight patients in the active group suf-
fered ICH versus three hundred and eighteen in the con-
trol group, indicated that there is no association
between statin and ICH (OR 1.08, 95 % CI 0.88–1.32, P
= 0.47). Meta regression analysis demonstrated there was
Ma et al. Lipids in Health and Disease  (2016) 15:43 Page 5 of 9
Table 2 Summary of clinical studies investigating the relationship between statin use and ICH
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no relationship between the risk of ICH and (i) the de-
gree of the LDL-C reduction (slope, 0.0043; SE, 0.0054;
95 % CI, −0.4831 to 0.0149; P = 0.43); (ii) the achieved
level of LDL-C in the active treatment group (slope,
−0.0049; SE, 0.0043; 95 % CI, −0.0133 to 0.0035; P =
0.26). In addition, the Helsinki ICH Study composed of
964 ICH patients [21] showed admission (23 % vs. 24 %,
P = 0.785), 3 months (34 % vs. 32 %, P = 0.449) and
12 months (38 % vs. 36 %, P = 0.602) mortality did not
differ between the patients who used statin before
hospitalization and those who did not. It suggested that
statin therapy before admission had no effect on the
prognosis of ICH patients. Another meta-analysis of 12
studies which included 1652 patients who used statins
before ICH and 5309 nonusers [14] demonstrated statin
did not have a significant effect on the improvement of
the admission, 30-day and 90-day mortality (OR 0.85,
95 % CI 0.70–1.03). The proportion of the patients re-
ceiving a Rankin score of 3–6 (OR 0.82, 95 % CI 0.60–
1.11) or 4–6 (OR 0.79, 95 % CI 0.43–1.45) was not chan-
ged when premorbid statin was used. In other words,
premorbid statin therapy did not improve the functional
outcome significantly [14]. Furthermore, the volume of
hematoma was not affected significantly with premorbid
statin therapy [14]. A population-based prospective co-
hort study also revealed statin therapy initiated during
admission or within 3 months after discharge did not in-
crease the risk of recurrent ICH [7].
Statins may promote ICH
The Stroke Prevention by Aggressive Reduction in Chol-
esterol Levels (SPARCL) study [37] is the only secondary
prevention study by now to evaluate the effect of statin
therapy in non-cardiac ischemic stroke or transient is-
chemic attack (TIA) associated with hypercholesterol-
emia. The study included 4731 patients, who had a
history of stroke or TIA within 1–6 months and a serum
LDL-C level of at least 100–190 mg/dl but did not have
any known coronary heart disease. These patients were
randomly allocated to the active group (80 mg atorva-
statin daily) or control group (matched placebo). The re-
sults showed that decreased cholesterol level was
associated with less risk of recurrent stroke. But the post
hoc analysis [10] found that there were more
hemorrhagic stroke patients in the treatment group than
those in the placebo group (2.3 % vs. 1.4 %, HR 1.68,
95 % CI 1.09–2.59). Cox multivariable regression ana-
lysis showed that a hemorrhagic stroke as the entry
event (HR 5.65, 95 % CI 2.82–11.30, p < 0.001), male
(HR 1.79, 95 % CI 1.13–2.84, P = 0.01), age (10 y incre-
ments, HR 1.42, 95 % CI 1.16–1.74, P = 0.001) and hav-
ing Stage 2 (JNC-7) hypertension (HR 6.19, 95 % CI
1.47–26.11, P = 0.01) were independently associated with
the risk of hemorrhagic stroke. Scheitz, JF et al. [1]
analyzed data from two European intravenous thromb-
olysis registries and found that 317 (22 %) used statins
before intravenous thrombolysis among 1446 acute is-
chemic stroke patients and the frequency of symptom-
atic ICH was 2 %, 6 %, and 13 % in patients with low-,
medium-, and high-dose statin (simvastatin 20, 40,
80 mg/d or equivalent) treatment, respectively (P < 0.01),
which indicated that there was a correlation between the
increasing dose of statin therapy and risk of ICH among
patients who had been treated with simvastatin or
atorvastatin.
These inconsistent results may be caused by differ-
ent population and dosage of stains when the rela-
tionship between stain therapy and ICH was studied.
As shown in Table 2, a majority of randomized con-
trolled trials [33] and the meta-analyses [35, 36]
which included the patients with a history of athero-
sclerotic cardiovascular disease or the subjects with
risk factors for atherosclerosis (such as diabetes,
hypertension or smoking) showed that statin use did
not affect the occurrence or outcome of ICH. But
certain patients with history of ICH or high risk of
ICH appear to be at increased risk of brain hemor-
rhages when exposed to high-dose statin [1, 37]. Mus-
tanoja et al. [21] reasoned that statin therapy could
increase the risk of ICH because low serum choles-
terol level may lead to the reduction of vessel resist-
ance to tension, resulting in higher risk of rupture
and hemorrhage.
Conclusion
Although epidemiological investigation found that
the population with lower serum TC and LDL-C
levels had a higher risk of ICH, the reduction of
blood lipid levels caused by statin therapy might not
increase the risk of ICH. Based on the current data,
we think statin use in the prevention and treatment
of atherosclerotic cardiovascular disease does not in-
crease the risk of ICH in most conditions. The
pleiotropic effects of statins such as inhibition of in-
flammation and protection of BBB may improve the
prognosis of acute hemorrhagic stroke patients. But
for elderly patients who have history of ICH and
poorly-controlled hypertension, statins especially
used in high dose, may increase the risk of ICH.
Therefore, patients with low TC and LDL-C and
high risk of ICH should be cautious in the usage of
statins.
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